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ABSTRACT  
We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine-
associated sarcoma given postsurgical curative (n=46, most with clean margins) or 
coarse fractionated radiotherapy (n=27, most with either macroscopic disease or dirty 
margins). The former animals displayed a median survival of 43 months and a median 
progression free interval (PFI) of 37 months, the latter reached a median survival of 24 
months and a median PFI of 10 months. In cats undergoing coarse fractionated therapy, 
factors predictive of a better outcome included lack of visible mass (n=10) as opposed 
to macroscopic disease (n=17, survival: 30 vs. 7 months, P=0.025; PFI: 20 vs. 4 months, 
P=0.01), adjuvant chemotherapy for gross disease (n=5/17, survival: 29 vs. 5 months, 
P=0.04) and a smaller number of surgeries preceding radiation therapy (Coeff=0.41, 
P=0.03). The Ki67-index was not predictive for survival. We concluded that 
postsurgical curative and coarse fractionated radiotherapy are both effective legitimate 
options for managing vaccine-associated sarcomas.  
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INTRODUCTION 
In the US cat population feline vaccine-associated sarcomas have an incidence of 
approximately 1/10’0001-3 to 1/10004 cats. One study in Germany estimated the 
incidence in this country to one case per 1000 cats5. Vaccine-associated sarcomas 
account for about 40% of all feline skin tumours6-8 and are the most frequent skin 
tumour in this species5. 
 
Although the pathogenesis of vaccine-associated sarcoma has not been definitively 
elucidated, it is believed to involve chronic local inflammation, which has been 
associated with the adjuvant in the vaccines1,2,9,10 and age-related immunodeficiency11. 
In addition, there have also been single reports of sarcoma development after the 
injection of other agents like methylprednisolone or penicillin12, and lufenuron13; even 
suture material was associated with the formation of fibrosarcomas14.  
 
Vaccine-associated sarcomas are highly invasive and often rapidly growing neoplasms. 
The evolution of treatment from single15-17 to multimodality18-21 therapy has resulted in  
longer progression free interval (PFI) and survival time. For example, in cats treated 
with surgery only the median survival time was 576 days17, in cats treated with 
chemotherapy only there was a 50% overall response rate and the median survival of the 
responders was 242 days16. In contrast, in cats undergoing multimodality treatment, 
radiation therapy prior to surgery resulted in a median survival time of 600 days20, and 
when radiation therapy was applied after surgery the median survival time was 730 
days18. But despite the combination of aggressive surgery and curative radiation 
therapy, treatment still fails in many patients. For this reason and because of its high 
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costs and time requirements, curative radiation therapy is not always an acceptable 
option for the owners. A coarse fractionation protocol was designed as an alternative. 
To the authors’ knowledge such a protocol has not been published so far for the therapy 
of vaccine-associated sarcomas.  
 
Vaccine-associated sarcomas have histologic characteristics considered either unique53 
or suggestive for this diagnosis22 as opposed to sarcomas not associated with 
vaccination. In addition to a broad spectrum of histologic types, they usually display 
peripheral inflammation consisting predominantly of lymphocytes and smaller number 
of plasma cells usually located around blood vessels23. The presence of peripheral 
aggregates of macrophages containing intracytoplasmic globular grey–brown material, 
which has been shown to contain aluminium, supports the diagnosis of vaccine-
associated sarcoma24.  
 
Both, histologic features of soft tissue sarcomas and tumour proliferation index have 
been examined in human and animal tumours. High tumour proliferation has been 
shown to correlate with aggressive behaviour in soft tissue sarcomas in humans25-29. 
Among several different possibilities to assess cell proliferation, the Ki67-index has 
been proposed as an intrinsic cell kinetic parameter with potential prognostic value in 
human soft tissue sarcomas25-29 and in canine tumours of various origins30-35, 47. In cats 
the Ki67-index was determined in apocrine sweat gland tumours36, melanocytic 
tumours37, squamous cell carcinomas38, lymphoma39 and mammary tumours40. One 
paper reports determination of the Ki67-index in feline vaccine-associated sarcomas41. 
No significant differences were found among the average proliferation rates determined 
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through measurements of the Ki67 reactivity at the tumour periphery among tumours of 
different histologic grade41. In addition, no significant difference was found between the 
proliferation index at the periphery and in central areas of the tumours. To our 
knowledge, the prognostic value of the Ki67-index has not yet been investigated in 
feline vaccine-associated sarcomas. Immunohistochemistry for Ki67 is well established 
for formalin fixed, paraffin-embedded tissues41,42. Therefore, it is well suited to perform 
retrospective studies.  
 
The two major aims of this retrospective study were 1) to evaluate the survival and PFI 
of curative versus coarse fractionated radiotherapy patients and 2) to determine the 
growth fraction of vaccine-associated sarcomas by Ki67 immunohistochemistry and the 
predictive value of the Ki67 labelling index. Additional variables assessed in the 
outcome analysis included demographical and clinical characteristics as well as 
histological parameters. 
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MATERIAL & METHODS 
Patients 
Medical records of all cats with histologically confirmed soft tissue sarcomas that 
underwent radiation therapy at the section of Diagnostic Imaging and Radiation 
Oncology at the Vetsuisse Faculty, University of Zurich, Switzerland between 1996 and 
2005 were reviewed. Only cats in which the tumour was determined to be vaccine-
associated on the basis of vaccination history and tumour location were included in the 
study. Thus, cats with sarcomas in locations not associated with vaccination (i.e. head, 
tail, oral cavity, distal regions of the limbs) were excluded. 
 
The diagnostic work up in the selected cats included a physical examination, a complete 
blood count and a chemistry panel to evaluate the general health status, and two lateral 
thoracic radiographs to search for distant metastases. Additional laboratory and 
diagnostic tests, as well as further imaging procedures were conducted as needed. 
Tumour location, presence and size of gross tumour or of a scar, as well as the number 
of previous excisions were gathered from the medical records for statistical analysis. 
 
Radiation Therapy  
All cats were treated with external beam megavoltage radiation. Radiation was 
delivered with a linear accelerator (Dynaray LA20, VARIAN, Zug, Switzerland) using 
9-16 MeV electrons. Treatment plans were calculated manually and the field 
dimensions were adjusted to enclose at least a 3 cm margin of presumed normal tissue 
adjacent to the tumour or the scar. Dose distribution was improved by using tissue-
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equivalent bolus material. Therapy plans were designed to maximally spare the spinal 
cord as well as the thoracic and abdominal organs.  
 
Irradiation was delivered with either a curative intent or a coarse fractionation protocol. 
The prescribed total dose for curative radiation therapy was either 48 Gy (12 x 4.0 Gy, 
delivered on a Monday-Tuesday-Thursday-Friday schedule) or 45 Gy (9 x 5.0 Gy, 
delivered on a Monday-Wednesday-Friday schedule). The standard protocol for coarse 
fractionation consisted of 4 fractions of 8.0 Gy each administered once a week. Criteria 
shifting decision towards the use of the coarse fractionation protocol included the 
presence of gross, nonresectable tumour, incomplete tumour excision, and concurrent 
medical problems. Surgical excision was considered “wide” if there was >1 cm of non-
neoplastic tissue around the tumour as determined by histological examination. If 
tumour cells did not extend to the excision margin, yet were within 1 cm of the margin, 
tumour excision was then called “clean but close”. In cases with either “wide” or “clean 
but close” margins, excision was considered as “complete” and for these cats curative 
radiation therapy was proposed to the cat owner. When neoplastic cells extended to the 
cut surface the margins were considered “dirty” and surgical excision was considered 
"incomplete". In these cats a coarse fractionation protocol was recommended. However, 
the final decision on which protocol to follow was left to the owner, which entails 
heterogeneity in the 2 treatment groups due to deviations from our recommendations. In 
some cases the margins had not been evaluated. These excisions were classified as “not 
assessable” and the decision towards one of the protocols was made on other variables, 
i.e. age, health, size of the scar, etc. Chemotherapy was recommended for all cats 
receiving coarse fractionated radiotherapy. 
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For radiation therapy, cats were anesthetized with either propofol (Propofol 1% 
Fresenius®, Fresenius Kabi AG, Stans, Switzerland) administered as the sole 
anaesthetic agent, or a combination of propofol/midazolam (Dormicum®, Roche 
Pharma AG, Reinach, Switzerland) or midazolam/ketamin (Narketan®10, Vetoquinol 
AG, Belp, Switzerland) administered to effect. Oxygen was provided by mask during 
radiation.  
 
Follow-up evaluation 
During the recheck examination three weeks after completion of radiotherapy, patients 
were assessed for acute side effects. Thereafter, the owners were instructed to consult 
for assessment of response to therapy at three-month intervals. These rechecks included 
regular thoracic radiography to evaluate for gross pulmonary metastasis. For cats that 
were not re-evaluated at the Vetsuisse Faculty, around the time of data analysis 
(September 20th 2005) the referring veterinarians and owners were queried by telephone 
interview about general health and tumour status and in case of death, if the cause was 
tumour-related or unrelated. No necropsies were performed. 
 
Progression free interval (PFI) was defined as the time from the start of radiotherapy at 
the Vetsuisse Faculty in Zurich to the onset of local recurrence or progression of gross 
disease or development of distant metastasis. Survival time was defined as the time 
between the start of radiotherapy and the date of death or the date of last follow-up or 
the date of data analysis for animals still alive. In animals with gross disease, response 
to treatment was defined as follows: a “complete response” was defined as 
disappearance of all measurable disease based on physical examination. “Partial 
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remission” indicated a tumour size reduction by ≥50%, with no new lesions developing. 
“Stable disease” was defined as less than 50% size decrease or up to 25% increase, and 
“progressive disease” indicated an increase in tumour measurements of ≥25%, or the 
development of new lesions or metastasis. At the occurrence of progressive disease, 
additional therapy was offered to all patients, regardless of the initial treatment. The 
options offered included either chemotherapy, a second round of radiation therapy, 
ancillary surgery or a combination of these modalities. 
 
Histopathological reassessment 
Paraffin blocks of the cases were obtained when available either from the archives of 
the Institute of Veterinary Pathology Zurich or from external diagnostic labs. 
Histopathology was performed (by FG and CE) using hematoxylin and eosin-stained 
sections. Depending on the predominant cellular morphology the tumours were 
classified either as fibrocytic (indicating a spindle-cell morphology), histiocytic or 
mixed cell type, referring to a mixed fibrocytic-histiocytic variant (Figure 1). Tumour 
grade based on cellular differentiation, presence and extension of necrosis within the 
neoplasm, and mitotic rate was assessed as described by Couto et al.41 (Table 1). This 
scheme was originally designed for the grading of soft tissue sarcomas in humans29 and 
later adapted for veterinary medicine by Kuntz et al.44  
 
Tissue array construction and immunohistochemistry  
The paraffin blocks obtained were used for tissue array construction. During 
histopathological analysis, areas with viable tumour tissue and areas with necrosis or 
with marked inflammatory infiltrates were labelled on each corresponding tissue 
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section. Labelling was used to select tumour regions in the paraffin blocks devoid of 
necrosis and marked inflammation for tissue array construction. Tissue cores (0.6 mm 
in diameter) were taken randomly from the preselected tumour areas; the number of 
cores taken per tumour ranged from 6 to 50, with a mean of 22. In a first step, between 
6 and 12 cores were taken depending on the cellular density of each particular tumour 
tissue. Further cores were added later as needed in order to reach the minimal number of 
cells required for the Ki67 counts. Sections from the arrays were labelled 
immunohistochemically with antibodies specific for T or B lymphocytes and for Ki67.  
 
CD3 and CD79alpha: Immunohistochemistry with antibodies anti-CD3 (for T 
lymphocytes) and anti-CD79alpha (for B lymphocytes) was used to exclude tissue areas 
with marked inflammatory infiltrates for the subsequent Ki67 assessment. This was 
done to avoid erroneous counting of lymphatic cell nuclei, which was deemed to be an 
issue especially in tumour cores with a transversal plane of section. Hence, only areas 
with less than 10% positive cells for CD3 or CD79alpha were used to determine the 
numbers of Ki67 positive cells. For detection of CD3 positive cells a polyclonal anti-
human pan T-cell antibody (Dako Cytomation, Zug, Switzerland; Cat. Number A0452) 
was used. CD79alpha positive cells were labelled using a monoclonal anti-human pan 
B-cell antibody (Dako; Cat. Number M7051). In both cases sections were pretreated for 
20 min. in a pressure cooker at 98 °C in basic buffer (pH=8; Dako; Cat. number S2367). 
Endogenous peroxidase was inactivated by immersing the slides in peroxidase blocking 
solution (Dako) for 10 min at room temperature. The anti-CD3 antibody was diluted 
1:250, the anti-CD79alpha antibody was diluted 1:300, both antibodies were incubated 
for 1 h at room temperature. For detection of the primary antibody, the Detection Kit 
 11
(Dako) was applied according to the manufacturer's instructions. The reaction was 
visualized by means of an AEC chromogen (Dako) and the slides were counterstained 
with hemalum. A lymph node from a cat was used as a positive control, for negative 
controls incubation of the primary antibody was omitted. 
 
Ki67-index: The sections were labelled for Ki67 (monoclonal antibody anti-human 
Ki67, clone MIB-1; Dako, cat. number M7240) using a protocol previously described 
for cat tissues by Melzer et al.38 Positive and negative tissues included into the arrays 
comprised cores bearing a squamous cell carcinoma and normal skin including hair 
follicles and Musculi arrectores pilorum. The percentage of positive tumour cells was 
determined by computer-assisted manual counting. All slides were scanned with a 
ScanScope (Aperio Technologies, Inc., Vista, CA, USA) and snapshots of randomly 
chosen regions of each core were taken at 40x magnification using the computer 
program “Aperio ImageScope” version 7.1.32.1024 (Aperio Technologies, Inc., Vista, 
CA, USA). A sufficient number of fields were photographed to allow a minimum of 
700 neoplastic cells per tumour to be counted. A minimum number of six cores were 
assessed for each tumour. The number of cells counted per field varied depending on 
the cellular density of each tumour (Figure 1). Additional cores were added when 
needed to reach the minimal number of cells to be counted as indicated above. The 
Ki67-index was defined as the percentage of Ki67 positive tumour cells and was 
determined by dividing the number of positive cells by the total number of positive and 
negative tumour cells, multiplied by 100. 
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Statistical analysis 
To calculate the progression free interval (PFI) local recurrence, progression of gross 
disease and distant metastasis were defined as event. Animals that did not experience a 
PFI event by the time of data analysis or at last follow-up were censored. In the survival 
analysis deaths attributable to, or likely attributable to disease progression were 
considered events. Cats still alive at the time of data evaluation, or deceased due to a 
tumour-unrelated cause, or lost to follow-up were censored in the survival analysis. 
Median PFI and survival were compared with respect to demographical and clinical 
characteristics (i.e. age, sex, breed, weight, vaccination history, tumour location, 
radiation protocol, total dose (Gy), tumour margins, number of surgeries before 
radiation therapy, adjuvant chemotherapy, response after initial therapy) and 
histological parameters (i.e. cell type, grade, mitotic rate, amount of necrosis in the 
tumour, overall differentiation of the tumour tissue, presence of multinucleated giant 
cells, percentage of Ki67-positive cells) by the Kaplan-Meier method together with 
logrank (Mantel-Cox) and Breslow-Gehan-Wilcoxon tests and univariate proportional 
hazards analysis. Due to the low number of grade I tumours in this study, for statistical 
analysis it was necessary to dichotomize the cases into a low grade group (histological 
grade I and II) and a high grade group (histological grade III). In order to develop 
multiple Cox-regression models, predictors with a P<0.1 in the univariate analysis or 
otherwise relevant were included in the backward Cox-regression. The resulting final 
multiple models were as follows. For the evaluation of Ki67 in association with survival 
and PFI, three different predictors were considered: first Ki67 was examined in a 
continuous form, second a binary (0/1) variable with a cut-off by the median (10% 
positive cells) was computed and third a binary (0/1) variable with a cut-off of 20% 
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(positive cells) suggested by the ROC analysis was evaluated. The influence of the 
different tumour and patient characteristics as listed above on descriptors of 
proliferation was evaluated by using the Wilcoxon rank test and the Fisher’s exact test. 
For statistical analysis StatView 5.0.1 (SAS Institute Inc., Cary, North Carolina, USA) 
and SPSS 13.0. (SPSS Inc., Chicago, Illinois, USA) were used. Throughout the study, 
the results of statistical analysis with P-value smaller than 5% were considered to be 
significant. 
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RESULTS 
Demographics 
Of the 73 cats included in this study, 29 (40%) were neutered males and 44 (60%) were 
spayed females. The age of the cats ranged from 4.0 to 18.0 years, with both a mean and 
median age of 9.0 years. Breeds represented included 66 Domestic Short Hairs, four 
Persian, one Main Coon, one Oriental Shorthair, and one Turkish Angora. Weight 
ranged from 3.0 to 7.9 kg with a mean of 4.9 kg. All 73 cats were vaccinated at least 
once in their life against feline viral panleukopenia/rhinothracheitis/calicivirus, and/or 
FeLV, and/or rabies. Primary tumour location included the neck/scapular/interscapular 
region (59%), the thoracic and abdominal wall (23%), or the flank/lumbar region (18%). 
All 73 patients were followed up to death or the time of data analysis except for one cat 
lost to follow-up. Thirty-two patients died or were euthanized due to tumour-related 
disease, 24 due to tumour-unrelated disease (i.e. car accident, heart failure, pulmonary 
edema, pleural effusion, liver tumour, renal failure, diabetes mellitus, ileus, ascites, 
etc.), and in three cases the cause of death could not be assessed. Metastases were not 
observed in any of the cats during or after therapy. 
 
Radiation Therapy 
In this and in the following paragraphs, details pertaining to clinical characteristics and 
to therapeutic modalities of the cats examined in the study are given. The most 
important information is summarized in Table 2. 
A total of 46 cats received curative radiation therapy. In three of these cats there was a 
visible mass. Response was complete in one cat, which underwent surgery after 
radiation therapy. Stable disease was observed in the other two cats. A total of 27 cats 
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were treated with the coarse fractionation protocol. The majority (17/27; 63%) of these 
cats presented with macroscopic disease. Of those 17 patients, two had a complete 
response, which allowed post-radiation surgical excision, 7 cats had a partial remission, 
7 cats had stable disease and one cat had progressive disease during radiation therapy.  
 
Adverse effects of radiation were reported to be mild and self-limiting with only dry 
desquamation, alopecia and depigmentation of the irradiated field. Negligible 
differences in intensity of side effects between curatively treated cats and those 
receiving coarse fractionated therapy were found, but the former animals appeared to 
have side effects more frequently. There were no differences in the adverse effects 
between cats that received concurrent chemotherapy and those that had radiation 
therapy as a sole treatment modality. 
 
Surgery  
Of all 46 cats receiving curative radiation therapy, 45 cats had one (n=24), two (n=16), 
three (n=4) or four (n=1) surgeries prior to radiation. Two of these cats already 
developed tumour recurrence before radiation therapy had started and these cats were 
therefore irradiated in the gross disease setting. In one of these cats tumour margins 
were dirty and in the other cat tumour margins were not assessable. A third cat 
underwent surgery after radiation therapy; the tumour was completely excised. 
Altogether, tumour excision was complete in 33/46 (72%) cases (margins were wide in 
22 cats and clean but close in 11 cats) and incomplete excision was found in 6/46 (13%) 
animals. In the remaining 5 cases (11%) completeness of excision was not assessable.  
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Of all 27 cats treated with the coarse fractionation protocol, 10 cats had prior surgery 
and were free of gross disease at the time of irradiation, and two cats irradiated in the 
gross disease setting underwent surgery after radiation therapy. Of the 10 cats that had 
surgery before radiation therapy, four had one surgery, three had two surgeries, one had 
three surgeries and two animals had four surgeries prior to radiation therapy. Margins 
were dirty in 7 out of these ten (70%) cats, clean but close in one (10%), and not 
assessable in two (20%) animals. In the two cats with surgery after radiotherapy, 
margins were wide in one cat and clean but close in the other.  
 
Chemotherapy  
Only one of the curatively treated cats received chemotherapy. It consisted of 
doxorubicin and was administered concurrently to radiation therapy. Altogether 13 of 
the 27 irradiated cats treated with a coarse fractionation protocol received additional 
chemotherapy. In 11 of these cats chemotherapy was started together with radiation and 
in the remaining two cats it was started after radiation ended. This group comprised 8 
out of 10 animals with no visible mass and 5 out of 17 cats with macroscopic disease. In 
all cases doxorubicin (20 mg/m2 or 1 mg/kg administered in three sessions, except for 
two cats that received it only once, and one cat that received it 6 times) was used as a 
single agent, except in one case where cyclophosphamide (250 mg/m2 evenly 
distributed over four days) was added. The use of chemotherapy did not cause any 
treatment response delays in those animals that were treated with both chemotherapy 
and ionizing radiation. 
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Additional therapy 
Additional therapy was offered to all patients after progressive disease was observed, 
regardless of the initial treatment. In 15 curatively treated cats it consisted either of 
surgery (n=7), chemotherapy (n=1), radiation therapy (n=1) or a combination of these 
treatments (n=6). In 6/17 cats with macroscopic disease subjected to coarse fractionated 
therapy additional therapy consisted of either a second round of radiation therapy (n=3), 
ancillary surgery (n=2) or chemotherapy (n=1). Two cats with no visible mass treated 
with coarse fractionation protocol received additional therapy consisting of a 
combination of these modalities. 
 
Histopathological reassessment 
Paraffin blocks from 55 of 73 cats were available for histopathological reassessment. In 
the remaining cases no paraffin blocks were available. The tumours were classified as 
fibrocytic (n=25), histiocytic (n=4) or mixed cell type (n=26) in dependence of the 
predominant cellular morphology (Figure 1). The detailed results of histological grading 
are reported in Table 1. For statistical analysis 27 cats (49%) were assigned to the low 
grade group (comprising histological grade I and II) and 28 animals (51%) to the high 
grade group (histological grade III). Multinucleated giant cells did not appear in 
histological grade I tumours and were detected in only 6/25 grade II tumours and in 
20/28 grade III tumours.  
 
Ki67-index 
The mean number of cells counted to assess the Ki67-index was 1272 (range 711 - 
3015). Ki67 could be evaluated in 52/55 cases. Three cases were excluded: in one 
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instance, too many cells stained positive for CD3 and CD79alpha preventing proper 
identification of tumour cells for counting. And in two other cases it was not possible to 
count a minimum of 700 cells. Of the 52 cases evaluated, 36 were curatively treated and 
16 were treated with coarse fractionated radiotherapy. The percentage of Ki67 positive 
cells varied between 0% and 40%, with a mean of 14% (Figure 1). The Ki67-index did 
not correlate with grade, neither in a continuous form nor after grouping using any of 
the cut-offs (10%, 20%). 
 
PFI and survival 
The median follow-up time for all animals in this study was 21 months. The median 
follow-up time in the curative group was 25 months, while the group that received 
coarse fractionated therapy had a median follow-up of 10 months. For the censored 
animals in the curative group, the median follow-up time was 32 months and for the 
cats receiving coarse fractionated therapy, it was 12 months.  
The main data related to the PFI are summarized in tables 3a and 3b and in figures 2 and 
3. Curatively treated patients (n=46) had a median PFI of 37 months (95% CI 19 - 56 
months). In this group, 63% (n=29) of the animals were progression free after one year 
(95% CI 49% - 78%) and 60% (n=28) after two years (95% CI 45% - 75%). Fifty 
percent (n=23) of the cats were tumour-free at the time of data analysis and were 
therefore censored. The median PFI of all cats receiving coarse fractionated therapy 
(n=27) was 10 months (95% CI 8 – 15 months). Seven of these 27 patients (26%) were 
censored. Cats with no visible mass receiving coarse fractionated therapy (n=10) had a 
significantly longer median PFI (20 months, 95% CI 9 – 30 months) than those with 
macroscopic disease (n=17, 4 months, 95% CI 2 – 5 months; P=0.01). In the curatively 
 19
treated group the Ki67-index had no significant impact on PFI with any of the 
predictors examined. In the group treated with coarse fractionated radiotherapy the 
Ki67-index showed no significant influence on PFI when examined in a continuous 
form, a tendency towards a longer PFI in cases with more than 10% positive tumour 
cells (P=0.0815) and a significantly longer PFI in cases with more than 20% positive 
tumour cells (P=0.015, multiple Cox-regression analysis). Differentiation of no visible 
mass/macroscopic disease was the only other predictor of PFI for cats with coarse 
fractionation suggested by the backward Cox-regression (P=0.002). 
 
The main data related to survival are summarized in tables 3a and 3b and in figures 4 to 
6. Curatively treated cats (n=46) displayed a median survival time of 43 months (95% 
CI 40 – 46 months). Eighty-six percent (n=39) of these animals were alive after one 
year (95% CI 76% - 96%), 71% (n=33) after two years (95% CI 56 – 85%), and 68% 
n=31) after three years (95% CI 53% - 83%). Twenty-eight of the 46 (61%) cats in this 
group were still alive at the time of data analysis or dead due to tumour-unrelated 
disease, and were therefore censored. The median survival time for cats undergoing 
coarse fractionated therapy (n=27) was 24 months (95% CI 4 – 43 months). Fifty-nine 
percent (n=17) of these animals were alive after one year (95% CI 39% - 79%). Of the 
27 cats treated with coarse fractionated radiotherapy nine animals (33%) were censored. 
Patients with no visible mass receiving coarse fractionated therapy (n=10) lived 
significantly longer (median survival 30 months; 95% CI 21 – 40 months) than cats 
with macroscopic disease (n=17, median survival time of 7 months; 95% CI 5 – 10 
months; P=0.025). However, survival in cats with macroscopic disease was significantly 
prolonged, when adjuvant chemotherapy was used (median survival 29 months, 95% CI 
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11 – 46 months; P=0.04; n=5). In cats with no visible mass additional benefit of 
chemotherapy over coarse fractionated radiotherapy alone could not be evaluated 
statistically. The Ki67-index did not correlate in any of the forms examined with 
survival neither in curatively treated patients nor in animals receiving coarse 
fractionated therapy. 
 
Tumour margins had no significant impact on outcome. In curatively treated cats, there 
was no significant difference in outcome neither between cats with wide (n=22) margins 
and cats with clean but close (n=11) margins nor between cats with complete (n=33) 
and incomplete (n=6) excisions. The outcome in the cats with wide excisions (n=22, 
including the cat with surgery after radiation therapy) and the cats with clean but close 
and dirty margins (n=11 and n=6, respectively) did not significantly differ either. When 
the outcome in the curative group was compared with a group where “non-confirming” 
cats as the one cat that received chemotherapy (n=1), the cats with dirty margins (n=6), 
those with gross disease (n=3), and those with non-assessable margins (n=5) were 
removed, the 95% confidence intervals for median PFI and survival time overlapped 
between these two groups. This suggests that no signs of bias were introduced by these 
“non-confirming” cats. This was also true when the outcome in the curative group was 
compared with another group where different “non-confirming” cats were removed 
including the one cat that received chemotherapy (n=1), the cats with gross disease 
(n=3), the cats with non-assessable margins (n=5) and those with wide excisions (n=21). 
No significant difference was observed when comparing the outcome in cats with dirty 
margins in the curative group (n=6) versus in the coarse fractionated therapy group 
(n=7). Low animal numbers prevented statistical analysis of the margin status in regard 
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to outcome in cats with no visible mass treated with the coarse fractionation protocol. 
The number of previous surgeries did not influence the outcome in curatively treated 
cats. In contrast, an increasing number of previous surgeries was significantly 
associated with a shorter survival time in cats undergoing coarse fractionated 
radiotherapy (Coeff=0.41, P=0.03). Additional therapy did not influence survival in the 
curatively treated cats as indicated by a lack of difference between outcomes in cats 
with and without additional therapy. In contrast, additional therapy resulted in 
significantly prolonged survival in cats subjected to coarse fractionated therapy (n=8, 
P=0.001).  
None of the further demographical, clinical and histological parameters tested correlated 
with outcome. 
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DISCUSSION 
In this study cats treated with a curative intent had a median survival of 43 months and a 
median PFI of 37 months. The latter variable was longer in our collective than in two 
previous studies (14 months; 22 months)18, 19 where radiation therapy was also applied 
after surgery. In a further previous study where radiation therapy was applied before 
surgery the PFI was shorter as well (20 months)21. Outcomes in our series were 
achieved with total doses of 45 or 48 Gy, which is considerably lower than those 
reported in the former two above mentioned studies (52 or 57 Gy)18, 19. This favourable 
outcome might be due to the large proportion of cats with complete surgical excision. 
However, in our study there was no significant difference in curatively treated cats 
between completely and incompletely excised tumours regarding survival and PFI. In 
contrast, previous investigations have shown that cats with complete surgical excision 
have a significant better outcome than those with incomplete excision15, 21, 45. A factor 
complicating the assessment of the prognostic significance of the tumour margins is that 
criteria for complete and incomplete excision were not defined15, 45 or differed21 from 
those of the present study. Although the data cannot be directly compared due to basic 
differences in the study designs, results of the present study support the notion that 
adding curative radiation after surgery improves outcome.  
 
In this study cats treated with a coarse fractionation protocol had a median survival of 
24 months and a PFI of 10 months. These times are somehow surprisingly long. To our 
knowledge, a coarse fractionation protocol has never before been reported for use in 
cats with vaccine-associated sarcoma. In our practice it turned out to meet a need of the 
owners because of its reduced costs and time requirements in contrast to the curative 
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protocol. It was primarily recommended for cats with incomplete excision because of 
their possible higher likelihood of recurrence and poor outcome15, 21, 45. The cats with no 
visible mass in this group had a median survival of 30 months and a median PFI of 20 
months. In a previous study the median time to first event for preoperative curative 
radiation followed by an incomplete excision was 292 days (10 months)21. In another 
study, Bregazzi et al. irradiated microscopic remnants at the surgical site with curative 
intent and administered doxorubicin afterwards. The animals in that report reached a 
median PFI of 661 days (22 months)19, which is similar to the figure found in our study 
(20 months). However, a smaller number of fractions and a lesser total dose were used 
in our patients compared to the Bregazzi study. In both studies (ours and Bregazzi’s), 
radiation therapy was applied after surgery. Therefore, although the overall number of 
animals used in this study was low, our data suggest that a postsurgical coarse 
fractionation protocol may have a role in the management of cats with no visible mass 
and warrants further prospective evaluation.  
In cats with gross disease and treated with a coarse fractionation protocol adjuvant 
chemotherapy had a positive effect on survival (the median survival increased from 5 
months in cats without chemotherapy, n=12, to 29 months in cats receiving 
chemotherapy, n=5, P=0.04) but not on PFI. This survival data must be interpreted 
cautiously because of a possible influence of additional therapy that was applied after 
progressive disease. In addition, although chemotherapy was recommended for all cats 
receiving a coarse fractionation protocol, in this retrospective analysis it was not 
possible to determine how far clinical factors with influence on outcome (e.g. clinical 
signs or tumour size) played a role in the owner’s decision to apply this treatment. For 
these reasons and since the number of patients was small these results need to be 
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confirmed with a higher number of cats. Previous studies showed either no45 or only a 
modest16 effect of chemotherapy alone in animals with nonresectable tumours. In the 
latter investigation, approximately 50% of the cats responded to chemotherapy and 
showed a median survival of 242 days (8 months). In many cats with macroscopic 
disease coarse fractionated therapy implies a palliative intent. The primary goal of 
palliation is not to provide long-term or definitive tumour control but to induce pain 
relief or to reduce dysfunction associated with the tumour in patients in which other 
factors such as advanced metastatic disease or a severe concurrent disease are likely to 
lead to their demise53. However, as suggested from the current study, a coarse 
fractionation protocol in combination with chemotherapy may improve outcome, thus 
providing an additional therapeutic option for such cats. The appropriate treatment 
(either coarse fractionation radiation protocol, or chemotherapy or both) should be 
chosen individually from case to case. In conclusion, our data suggest that a coarse 
fractionation protocol also should have a place in the management of macroscopic 
disease.  
 
An important restriction applies to the survival data in general due to the retrospective 
character of this study. In fact, in many cases the cause of death was assessed by local 
veterinarians or by the owners themselves. Therefore, survival information must be 
interpreted cautiously. Similarly, the apparent lack of development of metastases during 
or after therapy in our collective may be a consequence of the lack of necropsy data. An 
absence of metastases is consistent with previous studies where vaccine-associated 
sarcomas were mainly locally invasive with no metastases or with low metastatic 
rates19, 46. In more recent reports, however, metastatic rates of 12%18 and 21%21, 55  have 
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been indicated. In a new study from 2008, Romanelli et al. cats with histologic grade 3 
tumours were significantly more likely to develop metastasis than cats with grade 1 and 
2 tumours55.  
In this study neither histologic grading nor its components taken individually were 
predictive of survival or PFI of cats diagnosed with vaccine-associated sarcomas. This 
is in contrast with human soft tissue sarcomas48, 49, 50 where histologic grading is the 
most important prognostic factor. A previous study in cats where the same grading 
system was used also failed to demonstrate such a correlation in vaccine-associated 
sarcomas41. This was also the case in a further study by Davidson15, who however used 
a different grading scheme. Our study confirms findings by Couto et al.41 that 
multinucleated giant cells do not occur in grade I vaccine-associated sarcomas. 
However, and contrary to what is described in human patients with soft tissue 
sarcomas51, 52, the presence of multinucleated giant cells does not appear to be useful to 
estimate prognosis in this tumour type. 
 
In our study, Ki67-index had no impact on survival neither in cats treated with a 
curative nor with a coarse fractionation protocol. However, when the 20% cut-off was 
used in the multivariate analysis for cats undergoing coarse fractionated radiotherapy 
the PFI was significantly prolonged (P=0.015). Due to the heterogeneity of treatments 
(no visible mass vs. macroscopic disease / with vs. without chemotherapy) in this group 
of patients these results should be evaluated critically. In addition, it cannot be 
completely ruled out that our selection method for appropriate cores for Ki67 counts, 
which tended to exclude tumour regions with strong inflammation constituted a bias. 
However, a previous study has shown no differences in the Ki67 labelling index 
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between samples from the centre of the tumours and the periphery41. Most inflammatory 
infiltrates are found in the latter. In conclusion, the results of the Ki67 evaluation were 
rather unexpected and this topic will require further studies. 
 
In summary, the results of the present study indicate that in vaccine-associated sarcomas 
the combination of surgery and subsequent radiation therapy is an effective option. 
Curatively treated cats displayed a median survival time of 43 months, while 86% of the 
cats were alive after one year (95% CI 76% - 96%), 71% after two years (95% CI 56 – 
85%), and 68% after three years (95% CI 53% - 83%), and their median PFI was 37 
months. A coarse fractionation protocol also appears to have a place in the management 
of vaccine-associated sarcomas. In this setting, factors predictive of a better outcome in 
our study include no visible mass as opposed to macroscopic disease, additional 
chemotherapy in cats with gross disease and a smaller number of surgeries performed 
before radiation therapy. The predictive value of the Ki67-index needs to be further 
clarified in feline vaccine-associated sarcomas. 
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Figure legends and Tables (Figures available on request) 
 
Table 1 - Criteria and results of histologic grading. Grade is the result of cumulative 
scoring by adding the individual scores for cellular differentiation, necrosis and mitotic 
rate. The results of this study are presented in bold (n=55). 
 
 
 
 
Table 2 - Clinical characteristics and adjuvant therapies in cats treated with curative or coarsely 
fractionated radiation therapy  
 
 
RT = radiation therapy; NA = not assessable; NR = not relevant 
 
RT 
protocol 
 No. of cats with tumour 
appearance and surgery 
as indicated 
 No. of cats with tumour 
margins as indicated 
 No. of cats with 
adjuvant 
chemotherapy 
 no visible mass 43  wide 
clean but 
close 
dirty 
NA 
21 
11 
6 
5 
 0 
1 
0 
0 
 gross disease 3     
Curative 
(n=46) 
   surgery after RT 1  wide 1  
 
0 
 no visible mass 10  dirty 
clean but 
close 
NA 
7 
1 
2 
 6 
1 
1 
 gross disease 17     Coarse  (n=27) 
   no surgery 
  surgery after RT 
15 
2 
 NR 
wide 
clean but 
close 
 
1 
1 
 
 
4 
1 
0 
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